Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 361

1.

Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus.

Tsuge M, Uchida T, Hiraga N, Kan H, Makokha GN, Abe-Chayama H, Miki D, Imamura M, Ochi H, Hayes CN, Shimozono R, Iwamura T, Narumi H, Suzuki T, Kainoh M, Taniguchi T, Chayama K.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e00183-17. doi: 10.1128/AAC.00183-17. Print 2017 Jun.

2.

Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection.

Klumpp K, Shimada T, Allweiss L, Volz T, Lütgehetmann M, Hartman G, Flores OA, Lam AM, Dandri M.

Gastroenterology. 2018 Feb;154(3):652-662.e8. doi: 10.1053/j.gastro.2017.10.017. Epub 2017 Oct 24.

PMID:
29079518
3.

Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice.

Uchida T, Imamura M, Hayes CN, Hiraga N, Kan H, Tsuge M, Abe-Chayama H, Zhang Y, Makokha GN, Aikata H, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00725-17. doi: 10.1128/AAC.00725-17. Print 2017 Sep.

4.

Latest developments in the treatment of hepatitis B.

Dandri M, Petersen J.

Minerva Gastroenterol Dietol. 2016 Mar;62(1):88-102. Epub 2015 Oct 8. Review.

PMID:
26448309
5.

Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.

Iannazzo S, Coco B, Brunetto MR, Rossetti F, Caputo A, Latour A, Espinos B, Bonino F.

Antivir Ther. 2013;18(4):623-33. doi: 10.3851/IMP2555. Epub 2013 Mar 13.

PMID:
23486701
6.
7.

Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.

Cai Q, Chen F, Shao X, Zhang X, Zhao Z, Gao Z.

Antivir Ther. 2015;20(2):217-24. doi: 10.3851/IMP2832. Epub 2014 Aug 20.

PMID:
25138110
8.

Effect of interferon-γ and tumor necrosis factor-α on hepatitis B virus following lamivudine treatment.

Shi H, Lu L, Zhang NP, Zhang SC, Shen XZ.

World J Gastroenterol. 2012 Jul 21;18(27):3617-22. doi: 10.3748/wjg.v18.i27.3617.

9.

The response to interferon is influenced by hepatitis B virus genotype in vitro and in vivo.

Zhang Y, Wu Y, Ye S, Wang T, Zhao R, Chen F, Abe K, Jin X.

Virus Res. 2013 Jan;171(1):65-70. doi: 10.1016/j.virusres.2012.10.027. Epub 2012 Nov 2.

PMID:
23123214
10.

Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.

Boglione L, Cariti G, Di Perri G, D'Avolio A.

J Med Virol. 2016 Nov;88(11):1953-9. doi: 10.1002/jmv.24534. Epub 2016 Apr 18.

PMID:
27017932
11.

Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.

Yeh ML, Peng CY, Dai CY, Lai HC, Huang CF, Hsieh MY, Huang JF, Chen SC, Lin ZY, Yu ML, Chuang WL.

PLoS One. 2015 Apr 2;10(4):e0122259. doi: 10.1371/journal.pone.0122259. eCollection 2015.

12.

Altered expression of interferon-stimulated genes is strongly associated with therapeutic outcomes in hepatitis B virus infection.

Han M, Li Y, Wu W, Zhang Y, Yan W, Luo X, Ning Q.

Antiviral Res. 2017 Nov;147:75-85. doi: 10.1016/j.antiviral.2017.10.003. Epub 2017 Oct 6.

PMID:
28988797
13.

A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy.

Colombatto P, Civitano L, Bizzarri R, Oliveri F, Choudhury S, Gieschke R, Bonino F, Brunetto MR; Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group.

Antivir Ther. 2006;11(2):197-212.

PMID:
16640101
14.

Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues.

Jansen L, Kootstra NA, van Dort KA, Takkenberg RB, Reesink HW, Zaaijer HL.

J Infect Dis. 2016 Jan 15;213(2):224-32. doi: 10.1093/infdis/jiv397. Epub 2015 Jul 27.

PMID:
26216905
15.

Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.

Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, Longerich T, Schirmacher P, Metzler F, Zankel M, Fischer C, Currie G, Brosgart C, Petersen J.

Hepatology. 2006 Sep;44(3):675-84.

PMID:
16941693
16.

Anti-HBV drugs suppress the growth of HBV-related hepatoma cells via down-regulation of hepatitis B virus X protein.

Zhang S, Gao S, Zhao M, Liu Y, Bu Y, Jiang Q, Zhao Q, Ye L, Zhang X.

Cancer Lett. 2017 Apr 28;392:94-104. doi: 10.1016/j.canlet.2017.02.003. Epub 2017 Feb 9.

PMID:
28192212
17.

CD56bright natural killer cells induce HBsAg reduction via cytolysis and cccDNA decay in long-term entecavir-treated patients switching to peginterferon alfa-2a.

Shi A, Zhang X, Xiao F, Zhu L, Yan W, Han M, Luo X, Chen T, Ning Q.

J Viral Hepat. 2018 Nov;25(11):1352-1362. doi: 10.1111/jvh.12946. Epub 2018 Jul 10.

PMID:
29888839
18.

HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?

Kao JH.

Liver Int. 2014 Feb;34 Suppl 1:112-9. doi: 10.1111/liv.12400. Review.

PMID:
24373087
19.

Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?

Viganò M, Invernizzi F, Lampertico P.

Liver Int. 2015 Jan;35 Suppl 1:107-13. doi: 10.1111/liv.12717. Review.

PMID:
25529095
20.

The effect of peginterferon alpha-2a vs. interferon alpha-2a on intrahepatic covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients.

Liu S, Zheng H, Huang Y, Li B, Dong Z.

Clin Res Hepatol Gastroenterol. 2016 Jun;40(3):304-308. doi: 10.1016/j.clinre.2015.06.023. Epub 2015 Sep 14.

PMID:
26382279

Supplemental Content

Support Center